Article
RU-486 (Mifepristone) ameliorates diabetes but does not correct deficient beta-adrenergic signalling in adipocytes from mature C57BL/6J-ob/ob mice.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity - 1 Oct 1997
Gettys T W, Watson P M, Taylor I L, Collins S
Abstract excerpt
OBJECTIVE: To investigate the role of hypercorticism in the development of compromised beta-adrenergic signalling in adipocytes of mature C57BL/6J-ob/ob mice. DESIGN AND EXPERIMENTAL UNITS: Mature male ob/ob mice and their lean littermates were treated with vehicle or the specific glucocorticoid receptor (GR) antagonist, RU-486 (30 mg/kg bw/d) for 21 d. MEASUREMENTS: Blood glucose, serum insulin, adipocyte Glut-4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
